681 related articles for article (PubMed ID: 15766296)
21. Comorbid mental disorders in substance users from a single catchment area--a clinical study.
Langås AM; Malt UF; Opjordsmoen S
BMC Psychiatry; 2011 Feb; 11():25. PubMed ID: 21314980
[TBL] [Abstract][Full Text] [Related]
22. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
[TBL] [Abstract][Full Text] [Related]
23. Age at onset and clinical correlates in body dysmorphic disorder.
Bjornsson AS; Didie ER; Grant JE; Menard W; Stalker E; Phillips KA
Compr Psychiatry; 2013 Oct; 54(7):893-903. PubMed ID: 23643073
[TBL] [Abstract][Full Text] [Related]
24. Impulse control disorders in adults with obsessive compulsive disorder.
Grant JE; Mancebo MC; Pinto A; Eisen JL; Rasmussen SA
J Psychiatr Res; 2006 Sep; 40(6):494-501. PubMed ID: 16430922
[TBL] [Abstract][Full Text] [Related]
25. Substance use problems and associated psychiatric symptoms among adolescents in primary care.
Shrier LA; Harris SK; Kurland M; Knight JR
Pediatrics; 2003 Jun; 111(6 Pt 1):e699-705. PubMed ID: 12777588
[TBL] [Abstract][Full Text] [Related]
26. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
Liraud F; Verdoux H
Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
[TBL] [Abstract][Full Text] [Related]
27. Psychiatric comorbidity and severity of dependence on substance users: how it impacts on their health-related quality of life?
Lozano ÓM; Rojas AJ; Fernández Calderón F
J Ment Health; 2017 Apr; 26(2):119-126. PubMed ID: 27128492
[TBL] [Abstract][Full Text] [Related]
28. [Prevalence and comorbidity of body dysmorphic disorder in psychiatric outpatients].
Vinkers DJ; van Rood YR; van der Wee NJ
Tijdschr Psychiatr; 2008; 50(9):559-65. PubMed ID: 18785103
[TBL] [Abstract][Full Text] [Related]
29. Insight in body dysmorphic disorder with and without comorbid obsessive-compulsive disorder.
Marazziti D; Giannotti D; Catena MC; Carlini M; Dell'Osso B; Presta S; Pfanner C; Mungai F; Dell'Osso L
CNS Spectr; 2006 Jul; 11(7):494-8. PubMed ID: 16816788
[TBL] [Abstract][Full Text] [Related]
30. Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders.
van der Meer J; van Rood YR; van der Wee NJ; den Hollander-Gijsman M; van Noorden MS; Giltay EJ; Zitman FG
Nord J Psychiatry; 2012 Sep; 66(4):232-8. PubMed ID: 22029732
[TBL] [Abstract][Full Text] [Related]
31. A comparison of quality of life and psychosocial functioning in obsessive-compulsive disorder and body dysmorphic disorder.
Didie ER; Walters MM; Pinto A; Menard W; Eisen JL; Mancebo M; Rasmussen SA; Phillips KA
Ann Clin Psychiatry; 2007; 19(3):181-6. PubMed ID: 17729020
[TBL] [Abstract][Full Text] [Related]
32. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders.
Icick R; Moggi F; Slobodin O; Dom G; Mathys F; van den Brink W; Levin FR; Blankers M; Kaye S; Demetrovics Z; van de Glind G; Velez-Pastrana MC; Schellekens ASA;
Eur Addict Res; 2020; 26(4-5):201-210. PubMed ID: 32570249
[TBL] [Abstract][Full Text] [Related]
33. Primary and secondary substance misusers: do they differ in substance-induced and substance-independent mental disorders?
Bakken K; Landheim AS; Vaglum P
Alcohol Alcohol; 2003; 38(1):54-9. PubMed ID: 12554609
[TBL] [Abstract][Full Text] [Related]
34. Prevalence and clinical characteristics of body dysmorphic disorder in adolescent inpatient psychiatric patients-a pilot study.
Jafferany M; Osuagwu FC; Khalid Z; Oberbarnscheidt T; Roy N
Nord J Psychiatry; 2019; 73(4-5):244-247. PubMed ID: 31074670
[No Abstract] [Full Text] [Related]
35. The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic.
Tsuang D; Cowley D; Ries R; Dunner DL; Roy-Byrne PP
J Clin Psychiatry; 1995 Dec; 56(12):549-55. PubMed ID: 8530330
[TBL] [Abstract][Full Text] [Related]
36. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the course of substance use disorders among individuals with and without generalized anxiety disorder in a nationally representative sample.
Magidson JF; Liu SM; Lejuez CW; Blanco C
J Psychiatr Res; 2012 May; 46(5):659-66. PubMed ID: 22444600
[TBL] [Abstract][Full Text] [Related]
38. Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates.
Zimmerman M; Mattia JI
Compr Psychiatry; 1998; 39(5):265-70. PubMed ID: 9777278
[TBL] [Abstract][Full Text] [Related]
39. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
40. Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness.
Phillips KA; Menard W; Pagano ME; Fay C; Stout RL
J Psychiatr Res; 2006 Mar; 40(2):95-104. PubMed ID: 16229856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
